Skip to content
Navigate to homepage - Cerba Research
Resource Library

Fact Sheet – Advancing Cell & Gene Therapy Trials With Confidence

Cerba Research is uniquely positioned to support your cell & gene therapy trial with a wide range of in-house laboratory services, supported by bespoke logistics solutions. We are also able to support sponsors with their assay development, including our regulatory and IVDR certification capabilities. One IVDR example is related to AAV ( ADA) ELISA assay.

Reach out to our experts and discover how we can help advance your research

Resource Library

Fact Sheet – Hematological Malignancies Trial Portfolio

Cerba Research has conducted ~80 hematological malignancy trials within the last 5 years alone. Download our fact sheet and discover our hematological malignancies trial portfolio with cutting-edge laboratory solutions.

Reach out to our experts and discover how we can help advance your research

Resource Library

Fact Sheet – Advancing Your Solid Tumor Trials With Our Cutting-Edge Assay Portfolio

Cerba Research has conducted nearly 200 oncology trials within the last 5 years alone, with 55%+ being solid tumors such as lung, breast, and colorectal cancers. The central and specialty laboratories’ expertise includes specialized assays such as next-generation sequencing (NGS), flow cytometry (FCM), immunohistochemistry (IHC), AI in image analysis, and NanoString®. Check our latest fact sheet to learn more about our highlights and capabilities.

Reach out to our experts and discover how we can help advance your research

Resource Library

Fact Sheet – Unveiling the Oncology Journey: Highlighting Cutting-Edge Capabilities

Cerba Research has conducted nearly 200 oncology trials within the last 5 years alone. Its experience extends to both solid and liquid tumors and includes specialized assays such as next-generation sequencing (NGS), flow cytometry (FCM), immunohistochemistry (IHC), and NanoString®. Check our latest fact sheet to learn more about our highlights and capabilities.

Reach out to our experts and discover how we can help advance your research

Resource Library

Fact Sheet – Virology Center of Excellence: Illuminating Insights Into Infectious Diseases

Experience the unparalleled activity of Cerba Research’s Infectious Diseases (ID) therapy sector, boasting a remarkable track record of over 600 executed trials in just the last 5 years.

Reach out to our experts and discover how we can help advance your research

Resource Library

Fact Sheet – Unlocking The Potential Of Rare Disease Drug Development

Discover the extraordinary world of rare diseases, where uniqueness defines the landscape. While these conditions may lack a singular definition, they encompass a myriad of fascinating conditions waiting to be understood and treated.

Reach out to our experts and discover how we can help advance your research

Resource Library

White Paper – The Importance Of NGS Panel Customization For Your Assays: Good Practices And Key Takeaways

As cancer remains a major global health concern, precision medicine brings hope for patients for improved treatments and outcomes. Explore the pivotal role of Next-Generation Sequencing (NGS) panel customization in driving advancements in oncology research. From biomarker identification to actionable mutation detection, molecular profiling forms the bedrock of precision medicine. Learn how NGS panel customization is revolutionizing this landscape, enabling simultaneous analysis of diverse genetic aberrations for a comprehensive cancer understanding.

Traditional methods like Sanger sequencing and PCR are limited to single-gene analysis, making them impractical for new target discovery. NGS’s ability to analyse millions of segments in parallel accelerates research, while customized panels provide deeper, cost-effective insights into genomic abnormalities.

Discover insights on:

  1. NGS Advantages: Delve into the superiority of NGS over traditional methods, facilitating efficient and sensitive analysis.
  2. Clinical Implementation: See how NGS is enhancing patient care through improved molecular profiling in clinical trials and practice.
  3. Personalized Therapies: Understand how tailored panels enable personalized and precise targeted therapies by identifying actionable mutations.
  4. Latest Techniques: Explore the application of NGS to formalin-fixed paraffin-embedded (FFPE) samples and the innovative use of circulating tumor DNA (ctDNA).

Elevate your understanding of precision oncology’s potential. Download our white paper to harness the benefits of NGS panel customization. Empower your oncology research and clinical practice with insights that will help transform your research and advance health for patients.

 

Reach out to our experts and discover how we can help transform research and advance health.

Resource Library

White Paper – Precision Medicine For Non-Small Cell Lung Cancer (NSCLC) – Emerging Trends In Molecular Analysis

Of all types of cancer, lung cancer caused more deaths worldwide than any other type of cancer. It also causes more deaths than breast and colorectal cancers combined. Patients with the most common lung cancer, non-small cell lung cancer (NSCLC), have higher survival rates than patients with small-cell lung cancer (SCLC), but the outcomes for both remain bleak. According to the National Cancer Institute, the five-year survival rate for NSCLC between 2004 and 2010 was 20.7% compared to only 6.3% for SCLC.2

NSCLC patients also have more promising and more precise, treatment options today compared to even 10 years ago. Advances in biomarker and precision medicine have led to the development of immunotherapies and targeted novel treatments that have the potential to improve patient outcomes. In the United States, the FDA has approved dozens of biomarker-driven therapies for NSCLC, including ALK, EGFR, and ROS1 inhibitors. Meanwhile, more than 1,200 treatments are in development.

Discover the latest trends in precision medicine for NSCLC in this white paper

Reach out to our experts to see how we can help advance your clinical trial

Resource Library

Brochure – Cerba Research Genomics Experience In Oncology

Since 1992, Cerba Research/Healthcare has pioneered the art of human genetic testing, Cerba Healthcare builds the start of the art in human genetic testing by being the first laboratory in Europe to introduce Genetic testing.

Thanks to this experience, we are able to collaborate with the life science community to provide the most suitable genomic service and enhance the power of your genetic material.

Cerba Research can work with you to select the most suitable platform and assay to reach your project expectations.

Discover all our capabilities in our latest Genomics Brochure

Reach out to our experts and discover how we can help you transform research and advance health in the field of genomics.

Resource Library

White Paper – Nonnegotiable Central Laboratory Capabilities For I/O Clinical Trial Success

In immuno-oncology (I/O), meeting budget and timeline expectations in the journey from translational research to commercialization is a challenge. You need expert, integrated central laboratory and diagnostic solutions delivered by top scientists who will help you assess needs and generate early insights that optimize your protocol.

What else should you look for in a clinical laboratory partner? Along with access to a sizable patient database, impeccable performance across the globe, and I/O experience, three main testing capabilities are mandatory for success in this field: immunohistochemistry, flow cytometry, and next-generation sequencing.

Reach out to our experts & discover how we can help you transform research and advance health